共 50 条
- [1] Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE openJOURNAL OF CROHNS & COLITIS, 2018, 12 : S49 - S49Sands, B. E.Moss, A. C.Armuzzi, A.Marshall, J. K.Lindsay, J. O.Sandborn, W. J.Danese, S.Tsilkos, K.Lawendy, N.Zhang, H.Friedman, G. S.Chan, G.Krichbaum, D. W.Su, C.
- [2] Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE OpenJOURNAL OF CROHNS & COLITIS, 2022, 16 : I380 - I381Allegretti, J. R.Gecse, K. B.Chiorean, M. V.Argollo, M.Guo, X.Lawendy, N.Su, C.Mundayat, R.Paulissen, J.Salese, L.Irving, P. M.
- [3] Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE OpenJOURNAL OF CROHNS & COLITIS, 2022, 16 : I380 - I381Allegretti, J. R.Gecse, K. B.Chiorean, M. V.Argollo, M.Guo, X.Lawendy, N.Su, C.Mundayat, R.Paulissen, J.Salese, L.Irving, P. M.
- [4] Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension studyJOURNAL OF CROHNS & COLITIS, 2020, 14 : S110 - S111Sands, B. E.Moss, A. C.Armuzzi, A.Marshall, J. K.Lindsay, J. O.Sandborn, W. J.Danese, S.Zeroncio, M.Modesto, I.Salese, L.Lawendy, N.Zhang, H.Su, C.
- [5] EFFICACY AND SAFETY OF ESCALATION TO TOFACITINIB 10 MG BID FOR PATIENTS WITH UC FOLLOWING LOSS OF RESPONSE ON 5 MG BID MAINTENANCE THERAPY: RESULTS FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDYGASTROENTEROLOGY, 2020, 158 (06) : S1189 - S1190Sands, Bruce E.Moss, AlanArmuzzi, AlessandroMarshall, John K.Lindsay, JamesSandborn, William J.Danese, SilvioZeroncio, MarcoModesto, IreneSalese, LeonardoLawendy, NervinZhang, HaiyingSu, Chinyu
- [6] Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE OpenALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (02) : 271 - 280Sands, Bruce E.Armuzzi, AlessandroMarshall, John K.Lindsay, James O.Sandborn, William J.Danese, SilvioPanes, JulianBressler, BrianColombel, Jean-FredericLawendy, NervinMaller, EricZhang, HaiyingChan, GarySalese, LeonardoTsilkos, KonstantinosMarren, AmySu, Chinyu
- [7] EFFICACY OF TOFACITINIB DOSE ESCALATION TO 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS AFTER COMPLETING MAINTENANCE THERAPY IN REMISSION AND LOSING RESPONSE: DATA FROM OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDYGASTROENTEROLOGY, 2020, 158 (06) : S1195 - S1195Rubin, David T.Dubinsky, Marla C.Panes, JulianWu, Deng-ChyangLawendy, NervinGuo, XiangLai, ChacunKwok, KennethSu, ChinyuSalese, Leonardo
- [8] Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustainJOURNAL OF CROHNS & COLITIS, 2020, 14 : S120 - S121Dubinsky, M. C.Chou, J. W.Su, C.Wang, W.Modesto, I.Guo, X.Vermeire, S.
- [9] TIME TO LOSS OF EFFICACY AMONG PATIENTS IN REMISSION FOLLOWING INDUCTION TREATMENT WITH TOFACITINIB 10 MG BID WHO REDUCED TOFACITINIB DOSE OR DISCONTINUED TOFACITINIB IN OCTAVE SUSTAINGASTROENTEROLOGY, 2020, 158 (06) : S1196 - S1196Dubinsky, Marla C.Chou, Jen-WeiSu, ChinyuWang, WenjinModesto, IreneGuo, XiangVermeire, Severine
- [10] Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension studyJOURNAL OF CROHNS & COLITIS, 2020, 14 : S112 - S113Rubin, D. T.Dubinsky, M. C.Panes, J.Wu, D. C.Lawendy, N.Guo, X.Lai, C.Kwok, K.Su, C.Salese, L.